Cargando…

Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

INTRODUCTION: There is paucity of data related to potential gender differences in the use of interventions to prevent and treat cardiovascular disease (CVD) among HIV‐positive individuals. We investigated whether such differences exist in the observational D:A:D cohort study. METHODS: Participants w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatleberg, Camilla I, Ryom, Lene, El‐Sadr, Wafaa, Mocroft, Amanda, Reiss, Peter, De Wit, Stephane, Dabis, Francois, Pradier, Christian, d'Arminio Monforte, Antonella, Kovari, Helen, Law, Matthew, Lundgren, Jens D, Sabin, Caroline A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839235/ https://www.ncbi.nlm.nih.gov/pubmed/29509305 http://dx.doi.org/10.1002/jia2.25083

Ejemplares similares

Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study
por: Hatleberg, Camilla Ingrid, et al.
Publicado: (2014)

Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study()
por: Hatleberg, Camilla Ingrid, et al.
Publicado: (2019)

Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study
por: Smith, Colette, et al.
Publicado: (2014)

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study
por: Boyd, Mark A., et al.
Publicado: (2017)

Presence of the Metabolic Syndrome Is Not a Better Predictor of Cardiovascular Disease Than the Sum of Its Components in HIV-Infected Individuals: Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study
por: Worm, Signe W., et al.
Publicado: (2009)

Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration
por: Sabin, Caroline A., et al.
Publicado: (2016)

Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study
por: Kovari, Helen, et al.
Publicado: (2016)

Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States
por: Boettiger, David C, et al.
Publicado: (2021)

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study
por: Petoumenos, Kathy, et al.
Publicado: (2012)

Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study
por: Worm, Signe W, et al.
Publicado: (2013)

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study
por: Kamara, David A, et al.
Publicado: (2014)

A comparison of estimated glomerular filtration rates using Cockcroft−Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection
por: Mocroft, A, et al.
Publicado: (2014)

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study
por: Mocroft, Amanda, et al.
Publicado: (2015)

Chronic kidney disease in patients with normal eGFR at baseline: results from EuroSIDA
por: Ryom, L, et al.
Publicado: (2010)

Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature
por: Tincati, Camilla, et al.
Publicado: (2018)

Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV
por: Greenberg, Lauren, et al.
Publicado: (2023)

Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?
por: Tincati, Camilla, et al.
Publicado: (2020)

Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection
por: Augello, Matteo, et al.
Publicado: (2023)

Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting
por: Greenberg, Lauren, et al.
Publicado: (2022)

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
por: Mocroft, Amanda, et al.
Publicado: (2013)

Role of In Vitro Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients
por: Tincati, Camilla, et al.
Publicado: (2012)

Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy
por: Merlini, Esther, et al.
Publicado: (2011)

Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness
por: Tincati, Camilla, et al.
Publicado: (2020)

HIV-Infected Late Presenter Patients
por: D'Arminio Monforte, Antonella, et al.
Publicado: (2012)

Reply to Manfredi
por: Lichtner, Miriam, et al.
Publicado: (2015)

Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium
por: Neesgaard, Bastian, et al.
Publicado: (2020)

Invariant Natural Killer T (iNKT) Cells in HAART-Treated, HIV-Positive Patients with Bone and Cardiovascular Impairment
por: Tincati, Camilla, et al.
Publicado: (2014)

Correction to: Clinical management of ageing people living with HIV in Europe: the view of the care providers
por: Boffito, Marta, et al.
Publicado: (2020)

Clinical management of ageing people living with HIV in Europe: the view of the care providers
por: Boffito, Marta, et al.
Publicado: (2020)

Cardiovascular risk evaluation of HIV-positive patients in a case-control study: comparison of the D:A:D and Framingham equations
por: Markowicz, Samuel, et al.
Publicado: (2014)

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2020)

Reduced Central Memory CD4+ T Cells and Increased T-Cell Activation Characterise Treatment-Naive Patients Newly Diagnosed at Late Stage of HIV Infection
por: Bai, Francesca, et al.
Publicado: (2012)

Three case reports of West Nile virus neuroinvasive disease: lessons from real-life clinical practice
por: Falcinella, Camilla, et al.
Publicado: (2021)

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co‐infected HIV patients with cirrhosis
por: Willemse, Sophie, et al.
Publicado: (2019)

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE
por: Atkinson, Andrew, et al.
Publicado: (2020)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe
por: Mocroft, Amanda, et al.
Publicado: (2014)

A pilot study to determine the prevalence of HIV in persons presenting for care with selected conditions: preliminary results from the HIV in Europe study
por: Sönnerborg, A, et al.
Publicado: (2010)

A clinically useful risk-score for chronic kidney disease in HIV infection
por: Mocroft, Amanda, et al.
Publicado: (2014)

Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies
por: Kaulich-Bartz, Josee, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lobi1nlq5f48b48fqq3isgbn4a